Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Orders Label Revisions for Keytruda, Tecentriq, and More
January 11, 2024
- Handling of Big-Seller Candidates Is Top Priority as Japan Seeks Good Budget Balance: Minister
January 10, 2024
- Drugs Being Delivered to Quake-Hit Areas Day after Request: Minister
January 10, 2024
- Panels Urge OTC Switches “within 3 Years” for Drugs Sold Over the Counter in 2 or More Other Countries
January 5, 2024
- MHLW Unveils Draft Guidelines on Access to Intractable, Pediatric Disease Databases
January 5, 2024
- FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
- Japan Sets Up New Pharma Forum to Fight Drug Lag/Loss, Aims to Reflect Proposals in Honebuto
December 28, 2023
- Payers Reiterate Their Push for “1/2” LLP Copay Scenario for Price Gap from Generics
December 28, 2023
- Chuikyo Officially OKs Application of Elective Care for Off-Patent Branded Drugs
December 28, 2023
- Japan Maps Out Fresh 10-Year Strategy for Cancer Research
December 28, 2023
- Regulatory Panel Members Want Clearer Standard for SaMD Efficacy in 2-Stage Approval Scheme
December 27, 2023
- Health Minister Vows to Beef Up Japan’s Innovation Ecosystem in 2024
December 27, 2023
- Health Ministry Panel Explores Vision for Generic Industry, Eyes Structural Reform in 5 Years
December 26, 2023
- Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
- Japan Filing within 3 Months of Global Submission Eligible for Sakigake: MHLW
December 26, 2023
- Japan Ends Supply of Takeda/Novavax’s COVID Jab, 7.14 Million Doses Discarded
December 26, 2023
- Kaigen Pharma Hit by Suspension Order for Decades of Illicit Manufacturing
December 25, 2023
- MHLW Budget Hits Record High at 33.8 Trillion Yen, Ups Funding for Drug Innovation
December 25, 2023
- (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
- MHLW Announces “Innovation Box” Tax Regime: FY2024 Reform
December 25, 2023
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…